Kaynaklar

• Weinbrenner S, Assion HJ, Stargardt T, Busse R, Juckel G, Gericke CA. Drug prescription patterns inschizophrenia outpatients: analysis of data from a German health insurancefund. Pharmacopsychiatry 2009; 42(2): 66–71.
   PubMed Web of Science ®Google Scholar
• Williams CL, Johnstone BM, Kesterson JG, Javor KA, Schmetzer AD. Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia. Med Care 1999;37 (Lilly Suppl 4):S81–6.
   Web of Science ®Google Scholar
• Albayrak-Özalmete O, Ceylan ME, Özalmete O, Efe Sevim M. Yatan Şizofreni Hastalarında Çoklu Antipsikotik Kullanımı. Nöropsikiyatri Arşivi 2010; 47(1): 23–8.
   Web of Science ®Google Scholar
• Ensari H, Ceylan ME, Kılınc E, Kenar J. Turkiye'deki ruh hastalıkları hastanelerindeki psikofarmakolojik tedavilerin kalite yönünden değerlendirilmesi. Klinik Psikofarmakoloji Bulteni- Bulletin of Clinical Psychopharmacology 2004; 14(2): 68–78.
   Google Scholar
• Böke O, Sarısoy G, Akbaş S, Aker S, Korkmaz S, Alptekin Aker A, et al. Yatan hastalarda coklu antipsikotik kullanımı: Geriye donuk bir çalışma Klinik Psikofarmakoloji Bulteni- Bulletin of Clinical Psychopharmacology 2006; 16(3):167–73.
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161(Suppl 2):S1–S56.
   PubMed Web of Science ®Google Scholar
• Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller HJ; WFSBP Task Force on Treatment Guidelines for Schizophrenia. The World J Biol Psychiatry 2006; 7(1): 5–40.
   PubMed Web of Science ®Google Scholar
• Moore TA, Buchanan RW, Buckley PF, Chiles JA, Conley RR, Crismon ML, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry 2007; 68(11): 1751–62.
   PubMed Web of Science ®Google Scholar
• Üçok A, Soygür. Şizofreni Tedavi Klavuzu. Türkiye Psikiyatri Derneği Yayınları; 2010.
   Google Scholar
• Ganesan S, Taylor R, Rabheru K, Forbes I, Dumontet J, Procyshyn RM. Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr Res 2008; 98: 323–4.
   PubMed Web of Science ®Google Scholar
• Correll CU. Antipsychotic polypharmacy. Part 1: Shotgun approach or targeted cotreatment? J Clin Psychiatry 2008; 69(4): 674–5.
   Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical anti psychotic treatment. Am J Psychiatry 2006; 163(4): 600–10.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374(9690): 620–7.
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL. Management of treatment resistance in schizophrenia. Biol Psychiatry. 2001; 50(11): 898–911.
   PubMed Web of Science ®Google Scholar
• Freedman R. Schizophrenia. N Engl J Med 2003;349(18): 1738–49.
   PubMed Web of Science ®Google Scholar
• Honer WG, Procyshyn RM, Chen EYH, MacEwan GW, Barr AM. A translational research approach to poor treatment response in patients with schizophrenia: clozapine—antipsychotic polypharmacy. J Psychiatry Neurosci 2009; 34(6): 433–42.
   Web of Science ®Google Scholar
• Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158(4): 518–26.
   PubMed Web of Science ®Google Scholar
• Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010; 71(5): 566–73.
   PubMed Web of Science ®Google Scholar
• Barbui C, Signoretti A, Mulè S, Boso M, Cipriani A. Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009; 35(2): 458–68.
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, Kane JM, Leucht S, Correll CU, et al. Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009; 35(2): 443–57.
   PubMed Web of Science ®Google Scholar
• Taylor DM, Smith L. Augmentation of clozapine with a second antipsychotic- a meta-analysis of randomized, placebo-controlled studies. Acta Psychiatr Scand 2009; 119(6): 419–25.
   Web of Science ®Google Scholar
• Chan J, Sweeting M. Combination therapy with nonclozapine atypical antipsychotic medication: a review of current evidence. J Psychopharmacol 2007 21(6): 657.
   Web of Science ®Google Scholar
• Pandurangi AK, Dalkılıc A. Polypharmacy with Second-Generation Antipsychotics: A Review of Evidence. J Psychiatr Pract 2008; 14(6): 345–67
   Web of Science ®Google Scholar
• Goodwin G, Fleischhacker W, Arango C, Baumann P, Davidson M, de Hert M, et al. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009; 19: 520–32.
   PubMed Web of Science ®Google Scholar
• Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010, 23(2): 103–11
   PubMed Web of Science ®Google Scholar
• Shiloh R, Zemishlany Z, Aizenberg D, Radwan M, Schwartz B, Dorfman-Etrog P, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebocontrolled study. Br J Psychiatry 1997; 171: 569–73.
   PubMed Web of Science ®Google Scholar
• Wang J, Omori IM, Fenton M, Soares B. Sulpiride augmentation for schizophrenia. Cochrane Database Syst Rev 2010;(1): CD008125. pub2. DOI: 10.1002/14651858.
   Google Scholar
• Molina JD, Lerma-Carrillo I, Leonor M, Pascual F, Blasco-Fontecilla H, González-Parra S, et al. Combined treatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: a 1-year retrospective study. Clin Neuropharmacol 2009; 32(1): 10–5.
   Web of Science ®Google Scholar
• Assion HJ, Reinbold H, Lemanski S, Basilowski M, Juckel G. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry 2008;41(1): 24–8.
   PubMed Web of Science ®Google Scholar
• Genc Y, Taner E, Candansayar S. Comparison of clozapine-amisulpride and clozapine—quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther 2007; 24(1): 1–13.
   Web of Science ®Google Scholar
• Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Set al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162(1):130–6.
   PubMed Web of Science ®Google Scholar
• Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005; 66: 63–72.
   PubMed Web of Science ®Google Scholar
• Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006; 354(5): 472–82.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Henderson DC, Walsh JP, Culhane MA, Goff DC. Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo controlled trial. Schizophr Res 2007; 92(1–3): 90–4.
   PubMed Web of Science ®Google Scholar
• Cutler A, Ball S, Stahl SM. Dosıng Atypıcal Antıpsychotıcs. CNS Spectr 2008 13(5 Suppl 9):S1–S16.
   Web of Science ®Google Scholar
• Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry 2003; 64(2): 215–6.
   Web of Science ®Google Scholar
• Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005; 28(5): 220–4.
   Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, Sharma B, Borba CP, Forstbauer SI, et al. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009; 24(3): 225–32
   Web of Science ®Google Scholar
• Sacchetti E, Galluzzo A, Valsecchi P, Romeo F, Gorini B, Warrington L; MOZART Study Group. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res 2009; 113(1):112–21.
   PubMed Web of Science ®Google Scholar
• Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(6): 1386–92.
   Web of Science ®Google Scholar
• Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, et al. Aripiprazole augmentation in clozapine treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69(5):720–31.
   PubMed Web of Science ®Google Scholar
• Nosè M, Accordini S, Artioli P, Barale F, Barbui C, Beneduce R, et al. Rationale and design of an independentrandomised controlled trial evaluating the effectiveness of aripiprazole or haloperidol in combination with clozapine for treatment-resistant schizophrenia. Trials 2009; 10: 31.
   Web of Science ®Google Scholar
• Diaz P ve Hogan TP. Granulocytopenia With Clozapine and Quetiapine Am J Psychiatry 2001; 158(4):651.
   Web of Science ®Google Scholar
• Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasanov MA. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999; 18(2): 99–104.
   Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–96.
   PubMed Web of Science ®Google Scholar
• Mowerman S, Siris SG. Adjunctive loxapine in a clozapineresistant cohort of schizophrenic patients. Ann Clin Psychiatry 1996; 8(4): 193–7.
   Google Scholar
• Friedman J, Ault K, Powchik P. Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biol Psychiatry 1997; 42(6): 522–3.
   Web of Science ®Google Scholar
• Alkan Akdağ H, Kısa C, Bekki G, Göka E. Klozapin Tedavisini Pimozid ile Güçlendirme Yaklaşımı: Tedaviye Dirençli Bir şizofreni Olgusu. Nöropsikiyatri Arşivi 2010; 47(1): 74–7.
   Google Scholar
• Ganguly R, Kotzan J A, Miller S, Kennedy K, Martin BC. Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998–2000. J Clin Psychiatry 2004; 65(10): 1377–88.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Uchida H, Watanabe K, Nakajima S, Nomura K, Takeuchi H, et al. Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone. Hum Psychopharmacol 2008; 23(6): 455–63.
   Web of Science ®Google Scholar
• Lerner V, Chudakova B, Kravets S, Polyakova I. Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: A preliminary case series report. Clin Neuropharmacol 2000; 23(5): 284–6.
   Web of Science ®Google Scholar
• Seger A, Lamberti JS. Priapism associated with polypharmacy. J Clin Psychiatry 2001; 62(2): 128.
   Web of Science ®Google Scholar
• Bork JA, Rogers T, Wedlund PJ, de Leon J. A pilot study on risperidone metabolism: The role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 1999; 60(7): 469–76.
   PubMed Web of Science ®Google Scholar
• Ching-Hua L, Chao-Chan K, Li-Shiu C, Yeng-Hung C, Cheng- Chung C, Kuo-Hao H, et al. A randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia. Journal of Clinical Psychopharmacology. 2010; 30(5); 518–5.
   Web of Science ®Google Scholar
• Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvanitis LA. The safety and pharmacokinetics of quetiapine when co-administered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol 2002; 22(2): 121–30.
   Web of Science ®Google Scholar
• Nelson MW, Reynolds RR, Kelly DL, Conley RR. Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clin Neuropharmacol 2003; 26(6): 297–8.
   Web of Science ®Google Scholar
• Chue P, Welch R, Snaterse M. Combination risperidone and quetiapine therapy in refractory schizophrenia. Can J Psychiatry 2001; 46(1): 86–7.
   Web of Science ®Google Scholar
• Beelen AP, Yeo KT, Lewis LD. Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 2001; 20(4): 215–9.
   PubMed Web of Science ®Google Scholar
• Margolese HC, Kolivakis TT, Turnier L, Chouinard G. Clinical improvement with quetiapine augmentation of combination atypical antipsychotic pharmacotherapy in treatment resistant schizophrenia and schizoaffective disorder. Presented at 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, Dec. 10–14, 2000:188.
   Google Scholar
• Bozikas VP, Deseri C, Pitsavas S, Karavatos A. Antiaggressive Action of Combined Risperidone and Quetiapine in a Patient With Schizophrenia. Can J Psychiatry. 2003; 48(6): 426–7.
   Web of Science ®Google Scholar
• Ramaswamy S, Vijay D, William M, Sattar SP, Praveen F, Petty F. Aripiprazole possibly worsens psychosis. Int Clin Psychopharmacol 2004; 19(1): 45–8.
   Web of Science ®Google Scholar
• Lerner V, Bergman J, Borokhov A, Loewenthal U, Miodownik C. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005; 28(2): 66–71.
   Web of Science ®Google Scholar
• Hedges DW, Jeppson KG. New-onset seizure associated with quetiapine and olanzapine. Ann Pharmacother 2002; 36(3): 437–9.
   Web of Science ®Google Scholar
• Dunkley MJ, Reveley MA. Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma. J Psychopharmacol 2005; 19(1): 97–101.
   Web of Science ®Google Scholar
• Duggal HS. Aripiprazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry 2004; 49(2): 151.
   PubMed Web of Science ®Google Scholar
• DeQuardo JR. Increased efficacy with addition of clozapine to aripiprazole: Alternative explanations. J Clin Psychiatry 2005; 66(3): 396.
   Web of Science ®Google Scholar
• Gupta S, Sonnenberg SJ, Frank B. Olanzapine augmentation of clozapine. Ann Clin Psychiatry. 1998; 10(3): 113–5.
   Google Scholar
• Rhoads E. Polypharmacy of 2 atypical antipsychotics. J Clin Psychiatry 2000; 61(9): 678–80.
   Web of Science ®Google Scholar
• Kotler M, Strous RD, Reznik I, Shwartz S, Weizman A, Spivak B. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: Evidence for improvement of mood symptomatology. Int Clin Psychopharmacol 2004; 19(1): 23–6.
   PubMed Web of Science ®Google Scholar
• Raskin S, Durst R, Katz G, Zislin J. Olanzapine and sulpride: A preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia. J Clin Psychopharmacol 2000; 20(5): 500–3.
   Web of Science ®Google Scholar
• Pedrosa GF, Schneider C, Grohmann R, Rüther E. Incompatibility of olanzapine and amisulpride in multisystemic myotonic myopathy. Nervenarzt 2001; 72(9): 729–33.
   Web of Science ®Google Scholar
• Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004; 19(1): 56–8.
   Web of Science ®Google Scholar
• Minov C. Risk of QTc prolongation due to combination of ziprasidone and quetiapine. Psychiatr Prax 2004; 31(Suppl 1): S142–S4.
   Google Scholar
• Reeves RR, Mack JE. Worsening schizoaffective disorder with aripiprazole. Am J Psychiatry 2004; 161(7): 1308.
   Web of Science ®Google Scholar
• Englisch S, Enning F, Grosshans M, Marquardt L, Waltereit R, Zink M. Quetiapine combined with amisulpride in schizophrenic patients with insufficient responses to quetiapine monotherapy. Clin Neuropharmacol. 2010;33(5):227–9.
   Web of Science ®Google Scholar
• O'Shea M, Sazhin V, Collins A. Ventricular ectopics during crossover of atypical antipsychotics. Aust N Z J Psychiatry 2003; 37(6): 773–4.
   Web of Science ®Google Scholar
• Hanisch F, Friedemann J and Pillmann F. Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation. J Psychopharmacol 2010; 24(11): 1725–6.
   Web of Science ®Google Scholar
• Scott AIF. The ECT handbook: The third report of the Royal College of Psychiatrists' special committee on ECT. London: RCPsych Publications; 2005.
   Google Scholar
• Tharyan P, Adams CE. Electroconvulsive therapy for schizophrenia. The Cochrane Library 2009;4: CD000076.pub2. DOI: 10.1002/14651858.
   Google Scholar
• Chanpattana W, Andrade C. ECT for treatment-resistant schizophrenia: A response from the far east to the U.K. NICE report. J ECT 2006; 22(1): 4–12.
   Web of Science ®Google Scholar
• Ravanić DB, Pantović MM, Milovanović DR, Dukić-Dejanović S, Janjić V, Ignjatović DR, et al. Long-term efficacy of electroconvulsive therapy combined with different antipsychotic drugs in previously resistant schizophrenia. Psychiatr Danub. 2009; 21(2): 179–86.
   Web of Science ®Google Scholar
• Lykouras L, Alevizos B, Michalopoulou P, Rabavilas A. Obsessive-compulsive symptoms induced by atypical antipsychotics. A review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(3): 333–46.
   PubMed Web of Science ®Google Scholar
• Joffe G, Terevnikov V, Joffe M, Stenberg JH, Burkin M, Tiihonen J. Add-on mirtazapine enhances antipsychoticeffect of first generation antipsychotics in schizophrenia: a doubleblind, randomized, placebo-controlled trial. Schizophr Res 2009; 108(1–3): 245–51
   Web of Science ®Google Scholar
• Berk M, Gama CS, Sundram S, Hustig H, Koopowitz L, D'Souza R, et al. Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: a double-blind, randomised, placebo-controlled clinical trial. Hum Psychopharmacol 2009; 24(3): 233–8.
   PubMed Web of Science ®Google Scholar
• Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res 2007; 90(1–3): 186–97.
   PubMed Web of Science ®Google Scholar
• Englisch S, Knopf U, Scharnholz B, Kuwilsky A, Deuschle M, Zink M. Duloxetine for major depressive episodes in the course of psychotic disorders: an observational clinical trial. J Psychopharmacol 2009; 23(8): 875–82.
   Web of Science ®Google Scholar
• Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27(4): 380–6.
   PubMed Web of Science ®Google Scholar
• Rummel C, Kissling W, Leucht S. Antidepressants for the negative symptoms of schizophrenia. Cochrane Database Syst Rev 2006; 3:CD005581.
   Google Scholar
• Casey DE, Daniel DG, Tamminga C, Kane JM, Tran-Johnson T, Wozniak P, et al. Divalproex ER combined with olanzapine or risperidone for treatment of acute exacerbations of schizophrenia. Neuropsychopharmacology 2009; 34(5): 1330–8.
   PubMed Web of Science ®Google Scholar
• Schwarz C, Volz A, Li C, Leucht S. Valproate for schizophrenia. Cochrane Database Syst Rev 2008;(3):CD004028.
   Google Scholar
• Suzuki T, Uchida H, Takeuchi H, Nakajima S, Nomura K, Tanabe A, et al. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum. Psychopharmacol Clin Exp 2009; 24(8): 628–38.
   Web of Science ®Google Scholar
• Leucht S, Kissling W, McGrath J, White P. Carbamazepine for schizophrenia. Cochrane Database Syst Rev 2007;(3):CD001258.
   Google Scholar
• Glick ID, Bosch J, Casey DE. A double-blind randomized trial of mood stabilizer augmentation using lamotrigine and valproate for patients with schizophrenia who are stabilized and partially responsive. J Clin Psychopharmacol 2009; 29(3): 267–71.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Kiviniemi V. The efficacy of lamotrigine in clozapine resistant schizophrenia: a systematic review and meta-analysis. Schizophr Res 2009; 109(1–2):10–4.
   Web of Science ®Google Scholar
• Afshar H, Roohafza H, Mousavi G, Golchin S, Toghianifar N, Sadeghi M, et al. Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. J Psychopharmacol 2009; 23(2): 157–62.
   PubMed Web of Science ®Google Scholar
• Schönfeldt-Lecuona C, Wolf RC, Osterfeld ND, Vasic N, Connemann BJ, Schmid M, et al. Pregabalin in the treatment of schizophrenic anxiety. Pharmacopsychiatry 2009; 42(3): 124–5.
   PubMed Web of Science ®Google Scholar
• Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007;(3):CD003834.
   Google Scholar
• Leucht S, Kissling W, McGrath J. Lithium for schizophrenia revisited: a systematic review and meta-analysis of randomized controlled trials. J Clin Psychiatry 2004; 65(2): 177–86.
   PubMed Web of Science ®Google Scholar
• Citrome L. Adding lithium or anticonvulsants to antipsychotics for the treatment of schizophrenia: useful strategy or exercise in futility? J Clin Psychiatry 2009; 70(6): 932–3.
   PubMed Web of Science ®Google Scholar
• Sellin AK, Shad M, Tamminga C. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 2008; 13(11): 985–96.
   PubMed Web of Science ®Google Scholar
• Chung YC, Lee CR, Park TW, Yang KH, Kim KW. Effect of donepezil added to atypicalantipsychotics on cognition in patients with schizophrenia: an open-label trial. World J Biol Psychiatry 2009; 10(2): 156–62.
   PubMed Web of Science ®Google Scholar
• Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, et al. Efficacy and safety of donepezil inpatients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2008; 33(6): 1217–28.
   PubMed Web of Science ®Google Scholar
• Dyer MA, Freudenreich O, Culhane MA, Pachas GN, Deckersbach T, Murphy E, et al. High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr Res 2008; 102(1–3): 88–95.
   PubMed Web of Science ®Google Scholar
• Shim SS, Hammonds MD, Kee BS. Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site. Eur Arch Psychiatry Clin Neurosci 2008; 258(1): 16–27.
   PubMed Web of Science ®Google Scholar
• Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, et al. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res 2008; 106(2–3): 320–7.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Papadakis K, Csernansky J, Litman R, Volavka J, Jia XD, et al; MEM-MD-29 Study Group. A randomized, placebocontrolled study of memantine as adjunctive treatment in patients with schizophrenia. Neuropsychopharmacology 2009; 34(5): 1322–9.
   PubMed Web of Science ®Google Scholar
• Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J, et al. A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 2008; 33(3): 465–72.
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Miletich RS, Kohn PD, Esposito G, Carson RE, Quarantelli M, et al. Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat Neurosci 2002; 5(3): 267–71.
   PubMed Web of Science ®Google Scholar
• Roesch-Ely D, Gohring K, Gruschka P, Kaiser S, Pfüller U, Burlon M, et al. Pergolide as adjuvant therapy to amisulpride in the treatment of negative and depressive symptoms in schizophrenia. Pharmacopsychiatry 2006; 39(3): 115–6.
   Web of Science ®Google Scholar
• George MS, Molnar CE, Grenesko EL, Anderson B, Mu Q, Johnson K, et al. A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophr Res 2007; 93(1–3): 42–50.
   PubMed Web of Science ®Google Scholar
• Meyer-Lindenberg A, Weinberger DR. Intermediate phenotypes and genetic mechanisms of psychiatric disorders. Nat Rev Neurosci 2006; 7(10): 818–27.
   PubMed Web of Science ®Google Scholar
• Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J Clin Psychiatry 2009; 70(1): 104–12.
   PubMed Web of Science ®Google Scholar
• Freudenreich O, Henderson DC, Macklin EA, Evins AE, Fan X, Cather C, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry. 2009; 70(12): 1674–80.
   PubMed Web of Science ®Google Scholar
• Friedman JI, Carpenter D, Lu J, Fan J, Tang CY, White L, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008; 28(1): 59–63.
   Web of Science ®Google Scholar
• Akhondzadeh S, Mohammadi N, Noroozian M, Karamghadiri N, Ghoreishi A, Jamshidi AH, et al. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res 2009; 107(2–3): 206–12.
   Web of Science ®Google Scholar
• Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M, Rezazadeh SA. Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a doubleblind randomized placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(8): 1879–83.
   Web of Science ®Google Scholar
• Kulkarni J, de Castella A, Fitzgerald PB, Gurvich CT, Bailey M, Bartholomeusz C, et al. Estrogen in severe mental illness: a potential new treatment approach. Arch Gen Psychiatry 2008; 65(8): 955–60.
   PubMed Web of Science ®Google Scholar
• Ko YH, Lew YM, Jung SW, Joe SH, Lee CH, Jung HG, et al. Short-term testosterone augmentation in male schizophrenics: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2008; 28(4):375–83.
   PubMed Web of Science ®Google Scholar
• Bergemann N, Parzer P, Jaggy S, Auler B, Mundt C, Maier- Braunleder S. Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. Schizophr Bull 2008; 34(6): 1172–81.
   Web of Science ®Google Scholar
• Strous RD, Ritsner MS, Adler S, Ratner Y, Maayan R, Kotler M, et al. Improvement of aggressive behavior and quality of life impairment following S-adenosyl-methionine (SAM-e) augmentation in schizophrenia. Eur Neuropsychopharmacol 2009; 19(1):14–22.
   Web of Science ®Google Scholar
• Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010;71(2): 138–49.
   PubMed Web of Science ®Google Scholar
• Dickerson FB, Stallings CR, Origoni AE, Sullens A, Khushalani S, Sandson N, et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr Res 2009; 109(1–3):66–9.
   PubMed Web of Science ®Google Scholar
• Chen ZH, Wang GH, Wang XP, Chen RY, Wang HL, Yang MH, et al. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multicenterclinical trial. Hum Psychopharmacol 2008; 23(6): 465–70.
   Web of Science ®Google Scholar
• Salimi S, Fotouhi A, Ghoreishi A, Derakhshan MK, Khodaie- Ardakani MR, Mohammadi MR, et al. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32(3): 726–32.
   Web of Science ®Google Scholar
• Doruk A, Uzun O, Ozsahin A. A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol 2008; 23(4):223–7.
   Web of Science ®Google Scholar
• Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, et al. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Hum Psychopharmacol 2008; 23(2):79–86.
   PubMed Web of Science ®Google Scholar
• Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry 2009; 22(3):293–9.
   Web of Science ®Google Scholar
• Poyurovsky M, Fuchs C, Pashinian A, Levi A, Faragian S, Maayan R, et al. Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Psychopharmacology 2007; 192(3):441–8.
   PubMed Web of Science ®Google Scholar
• Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapineinduced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study. Am J Psychiatry 2008; 165(3): 352–8.
   PubMed Web of Science ®Google Scholar
• Joffe G, Takala P, Tchoukhine E, Hakko H, Raidma M, Putkonen H, et al. Orlistat in clozapine- or olanzapine treated patients with overweight or obesity: a 16-week randomized, double blind, placebo-controlled trial. J Clin Psychiatry 2008; 69(5): 706–11.
   PubMed Web of Science ®Google Scholar
• Baptista T, Uzcátegui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008; 159(1–2): 250–3.
   PubMed Web of Science ®Google Scholar
• Ziegenbein M, Calliess IT. Clozapine and ziprasidone: A useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci 2006; 18(2): 246–7.
   Web of Science ®Google Scholar
• Reinstein MJ, Sonnenberg JG, Mohan SC, Chasanov MA, Jones LE. Use of quetiapine to manage patients who experienced adverse effects with clozapine. Clin Drug Invest 2003; 23(1): 63–7.
   Web of Science ®Google Scholar
• Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009;113(1): 1–11.
   PubMed Web of Science ®Google Scholar
• Zhu B, Ascher-Svanum H, Faries DE, Correll CU, Kane JM. Cost of antipsychotic polypharmacy in the treatment of schizophrenia. BMC Psychiatry 2008;8:19.
   PubMed Web of Science ®Google Scholar
• Taylor D M. Antipsychotics and QT prolongation. Acta Psychiatrica Scandinavica 2003;107(2); 85–95.
   PubMed Web of Science ®Google Scholar
• Uçok A, Gaebel W. Side effects of atypical antipsychotics: a brief overview. World Psychiatry 2008; 7(1): 58–62.
   PubMed Web of Science ®Google Scholar
• Tümüklü MN, Alptekin K, Kırımlı Ö, Aslan Ö, Akdede BB, Badak Ö, et al. Arrhythmic Markers and Clozapine in Patients with Schizophrenia: Effect of 10 weeks Clozapine Treatment on Heart Rate Variability, Late Potentials and QT Dispersion. Klinik Psikofarmakoloji Bulteni- Bulletin of Clinical Psychopharmacology 2008;18(3): 167–73.
   Google Scholar
• Lewis R, Bagnall AM, Leitner M. Sertindole for schizophrenia. Cochrane Database Syst Rev. 2005;(3): CD001715.
   Google Scholar
• Gray JA, Roth BL. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007;12(10): 904–22.
   PubMed Web of Science ®Google Scholar
• Stahl SM. Symptoms and circuits, part 3: schizophrenia. J Clin Psychiatry 2004; 65(1): 8–9.
   Web of Science ®Google Scholar